Preparation of monovalent follistatin-like 3-Fc-fusion protein and evaluation of its effects on muscle mass in mice
Summary: Follistatin-like 3 (FSTL3) is an endogenous antagonist against transforming growth factor-β family ligands. Monovalent FSTL3-Fc fusion protein (mono-FSTL3-Fc) generated with knobs-into-holes technology overcomes limitations of current anti-myostatin therapies. We have developed a facile pro...
Main Authors: | Takayuki Ozawa, Kohei Miyazono, Masato Morikawa |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-12-01
|
Series: | STAR Protocols |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666166721005451 |
Similar Items
-
Systemic administration of monovalent follistatin-like 3-Fc-fusion protein increases muscle mass in mice
by: Takayuki Ozawa, et al.
Published: (2021-05-01) -
Follistatin-Like 1
by: Kai C. Wollert, MD
Published: (2016-06-01) -
In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance
by: Lu Shan, et al.
Published: (2021-09-01) -
p63 and Its Target Follistatin Maintain Salivary Gland Stem/Progenitor Cell Function through TGF-β/Activin Signaling
by: Sangwon Min, et al.
Published: (2020-09-01) -
Follistatin-related protein/follistatin-like 1 evokes an innate immune response via CD14 and toll-like receptor 4
by: Murakami, Kosaku
Published: (2012)